Dupixent Becomes First New Targeted Medication Approved in the U.S. for Chronic Spontaneous Urticaria in Over a Decade
"Finally, a new option for those suffering from CSU!"
"Is Dupixent covered by insurance? So many patients need this."
"This is great news, but what are the side effects?"
"I hope this brings relief to many who struggle with CSU. Fingers crossed!"
"Why did it take so long for a new treatment?"
"Amazing! Finally some hope for those affected by severe itching."
"How does Dupixent compare to traditional antihistamines?"
"This feels like a game changer. Excited to see the results!"
"Cheers to more treatment options for chronic conditions!"
"I wonder how quickly we can get access to this medication."
"Its about time! Patients have been waiting for years."
2025-04-18T15:15:00.000Z
Mei-Ling Chen
Source of the news: www.globenewswire.com